Newsletter
Persistent Systems has partnered with NVIDIA to build AI-powered solutions aimed at speeding up drug discovery.
What’s happening: the company has developed a platform called GenMolVS, which uses AI to simulate how molecules behave.
Instead of testing thousands of compounds in a lab, pharma companies can now screen and shortlist drug candidates virtually before moving to real-world experiments.
The why: drug discovery is usually a slow and expensive process that can take months or even years. By using AI-driven simulations, Persistent aims to cut this timeline down to days, while also reducing early-stage risks.
The solution runs on NVIDIA’s BioNeMo platform, AI tools, and high-performance computing infrastructure, allowing it to handle complex biological and chemical modelling at scale.
Why it matters: this is part of a larger shift where AI is entering core scientific research, not just automation or analytics. For pharma companies, faster discovery means lower costs, quicker drug development, and better success rates in clinical trials.
Big picture: on the economic side, the opportunity is huge. India’s digital health market is expected to cross $37 billion by 2030, and AI-led healthcare solutions are a key part of that.
Startups and IT firms are building tools for drug discovery, radiology, pathology, and hospital management, while global pharma companies are increasingly using India as a base for AI-driven research and clinical trials.
